[go: up one dir, main page]

DK1039882T3 - Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse - Google Patents

Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse

Info

Publication number
DK1039882T3
DK1039882T3 DK99946521.4T DK99946521T DK1039882T3 DK 1039882 T3 DK1039882 T3 DK 1039882T3 DK 99946521 T DK99946521 T DK 99946521T DK 1039882 T3 DK1039882 T3 DK 1039882T3
Authority
DK
Denmark
Prior art keywords
administration
controlled release
therapeutic formulation
release tolterodine
tolterodine
Prior art date
Application number
DK99946521.4T
Other languages
English (en)
Inventor
Lisbeth Nilvebrant
Birgitta Olsson
Ulla Hoeck
Torkel Gren
Anders Ringberg
Martin Wikberg
Bengt Hallen
Jan Stroembom
Bo Kreilgaard
Jacobsen Lene Orup
Helle Kristensen
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1039882(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9802864A external-priority patent/SE9802864D0/xx
Priority claimed from SE9803871A external-priority patent/SE9803871D0/xx
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of DK1039882T3 publication Critical patent/DK1039882T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK99946521.4T 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse DK1039882T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number Publication Date
DK1039882T3 true DK1039882T3 (da) 2011-01-24

Family

ID=26663376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99946521.4T DK1039882T3 (da) 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse

Country Status (31)

Country Link
US (1) US6770295B1 (da)
EP (2) EP1039882B1 (da)
CN (1) CN1239152C (da)
AP (1) AP1529A (da)
AR (1) AR029311A1 (da)
AT (1) ATE487471T1 (da)
AU (1) AU745190B2 (da)
BG (1) BG65168B1 (da)
CA (1) CA2311755C (da)
CY (1) CY1111088T1 (da)
CZ (1) CZ302630B6 (da)
DE (1) DE69942928D1 (da)
DK (1) DK1039882T3 (da)
EA (1) EA002720B1 (da)
GE (1) GEP20043354B (da)
HK (1) HK1034664A1 (da)
HU (1) HUP0100437A3 (da)
ID (1) ID25824A (da)
IL (1) IL136294A (da)
IS (1) IS2976B (da)
ME (1) ME00850B (da)
MY (1) MY127946A (da)
NO (1) NO329830B1 (da)
NZ (1) NZ504618A (da)
OA (1) OA11636A (da)
PT (1) PT1039882E (da)
SI (1) SI1039882T1 (da)
SK (1) SK287111B6 (da)
TR (1) TR200001998T1 (da)
UA (1) UA72882C2 (da)
WO (1) WO2000012069A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
SK6412002A3 (en) 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
EP1441707A1 (en) * 2001-11-09 2004-08-04 Pharmacia AB Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
US6773421B2 (en) 2001-12-14 2004-08-10 Kimberly-Clark Worlwide, Inc. Combination for managing the involuntary loss of bladder control
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
DE60332387D1 (de) * 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
BRPI0406861A (pt) * 2003-01-22 2006-01-03 Pfizer Health Ab Utilização de agente antimuscarìnico
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
PT2210605T (pt) 2003-11-04 2017-04-24 Tcd Royalty Sub Llc Formas de dosagem única diária de tróspio
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
CN1330297C (zh) * 2005-07-04 2007-08-08 宛六一 酒石酸托特罗定软胶囊及其制备方法
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛
EP3332788A1 (en) 2006-02-03 2018-06-13 Opko Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070248670A1 (en) * 2006-04-21 2007-10-25 Van Den Heuvel Dennie J M Tolterodine beads
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
CA2943032C (en) 2007-04-25 2019-05-07 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
EP2173329A1 (en) * 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
ES2783980T3 (es) 2010-03-29 2020-09-21 Opko Ireland Global Holdings Ltd Métodos y composiciones para la reducción de niveles de paratiroides
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
JP5642790B2 (ja) * 2010-08-03 2014-12-17 久光製薬株式会社 貼付剤及びその粘着力増強方法
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
AU666735B2 (en) * 1992-05-13 1996-02-22 Alza Corporation Transdermal administration of oxybutynin
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
AU7994694A (en) * 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法

Also Published As

Publication number Publication date
DE69942928D1 (de) 2010-12-23
PT1039882E (pt) 2011-01-03
NO329830B1 (no) 2011-01-03
CY1111088T1 (el) 2015-06-11
CA2311755C (en) 2010-03-23
TR200001998T1 (tr) 2001-01-22
AP2000001823A0 (en) 2000-06-30
AR029311A1 (es) 2003-06-25
ATE487471T1 (de) 2010-11-15
AU745190B2 (en) 2002-03-14
AU5891899A (en) 2000-03-21
HUP0100437A3 (en) 2002-08-28
MY127946A (en) 2007-01-31
IS5537A (is) 2000-06-15
SK287111B6 (sk) 2009-12-07
CA2311755A1 (en) 2000-03-09
AP1529A (en) 2006-01-03
HUP0100437A2 (hu) 2002-05-29
ME00850B (me) 2008-08-07
NO20002977L (no) 2000-06-09
US6770295B1 (en) 2004-08-03
IS2976B (is) 2017-07-15
CN1239152C (zh) 2006-02-01
EP1039882A1 (en) 2000-10-04
GEP20043354B (en) 2004-04-13
CZ302630B6 (cs) 2011-08-10
IL136294A (en) 2004-02-08
EA200000468A1 (ru) 2000-12-25
SK7492000A3 (en) 2001-02-12
NO20002977D0 (no) 2000-06-09
OA11636A (en) 2004-09-03
ID25824A (id) 2000-11-09
UA72882C2 (uk) 2005-05-16
HK1034664A1 (en) 2001-11-02
IL136294A0 (en) 2001-05-20
CZ20001924A3 (cs) 2001-04-11
SI1039882T1 (sl) 2011-01-31
CN1287484A (zh) 2001-03-14
EA002720B1 (ru) 2002-08-29
EP2153825A1 (en) 2010-02-17
EP1039882B1 (en) 2010-11-10
BG65168B1 (bg) 2007-05-31
NZ504618A (en) 2002-09-27
WO2000012069A1 (en) 2000-03-09
BG104476A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
DK1039882T3 (da) Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
DK0758244T3 (da) Doseringsformer af azithromycin med styret frigivelse
DK0941103T3 (da) Farmaceutisk præparat til behandling af diabetes
DK1140105T3 (da) Galantaminpræparat med styret frigivelse
DK1140034T3 (da) Formulering af divalproex-natrium med kontrolleret frigivelse
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DK200200116U4 (da) Mundhygiejnepræparat til behandling af halitosis
DK0746310T3 (da) Præparat med styret afgivelse
DK1083902T3 (da) Nye galeniske præparatformer af meloxicam til oral administrering
NO20001375L (no) Legemiddelformulering med kontrollert virkestoffrigivning
PT868911E (pt) Formulacoes de rapamicina para administracao oral
DK1007024T3 (da) Doseringsformer af sertralin med forsinket frigivelse
DK1171053T3 (da) Apparat til behandling af tandkaries
EE200100453A (et) Betahistiini reguleeritult vabastav preparaat
NO20014049D0 (no) Kontrollert frigjorings-formulering for behandling av COPD
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
DK1591122T3 (da) Fremgangsmåde til indgivelse af bisphosphonater
DK1345605T3 (da) Varmformet lægemiddelsammensætning til styret afgivelse af perindopril
DK1212095T3 (da) Fremgangsmåde til fremstilling af en formulering med opretholdt frigivelse
ID27014A (id) Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi
DK0859595T3 (da) Terapeutisk præparat til transdermal indgivelse af aktive sfoffer gennem huden